Molecular-cytogenetic analysis of HER-2/neu gene in BRCA1-associated breast cancers

• Published in: Cancer research (Chicago, Ill.) Ill.), 2002-03, Vol.62 (5), p.1481-1488
• Main Authors: GRUSHKO, Tatyana A, BLACKWOOD, M. Anne, SCHUMM, Phil L, HAGOS, Fitsum G, ADEYANJU, Moses O, FELDMAN, Michael D, SANDERS, Melinda O, WEBER, Barbara L, OLOPADE, Olufunmilayo I
• Format: Article
• Language: English
• Subjects: Adult; Aged; Biological and medical sciences; Breast Neoplasms - genetics; Chromosomes, Human, Pair 17; Female; Gene Amplification; Gene Dosage; Genes, BRCA1; Genes, erbB-2; Gynecology. Andrology. Obstetrics; Humans; Loss of Heterozygosity; Mammary gland diseases; Medical sciences; Middle Aged; Receptor, ErbB-2 - analysis; Tumor Cells, Cultured; Tumors
• ISSN: 0008-5472; 1538-7445

The BRCA1 tumor suppressor gene and the HER-2/neu oncogene are located in close proximity on the long arm of chromosome 17 (17q11-21). Absence of BRCA1 or functional overexpression of the HER-2/neu gene presumably contributes to the somatic phenotype of breast cancer in premenopausal women, characterized by unfavorable prognostic features such as high tumor grade, hormone receptor negativity, and high proliferation rate. To examine whether amplification of HER-2/neu contributes to the aggressive biology of BRCA1-associated tumors, we have performed fluorescence in situ hybridization on formalin-fixed paraffin-embedded breast tumor tissue sections from 53 BRCA1 mutation carriers and 41 randomly selected, age-matched sporadic breast cancer cases. Although BRCA1-associated and sporadic tumors were equally likely (19% versus 22%) to exhibit HER-2/neu amplification [defined as a ratio of HER-2/neu copies to chromosome 17 centromere (CEP17) copies > or = 2], 6 (15%) of the sporadic tumors were highly amplified (defined as a ratio greater-than-or-equal 5) versus none of the BRCA1-associated tumors (P = 0.048). HER-2 protein overexpression as measured by immunohistochemical analysis was not observed among the BRCA1-associated cases (P = 0.042). Four of 21 (19%) sporadic tumors exhibited strong membranous staining of HER-2 (intensity level of 3+) as compared with 0 of 39 BRCA1-associated tumors. Our data suggest that a germ-line mutation in the BRCA1 tumor suppressor gene is associated with a significantly lower level of HER-2/neu amplification. Thus, it is possible that BRCA1-associated and HER-2/neu-highly amplified tumors progress through distinct molecular pathways, and the aggressive pathological features of BRCA1-associated tumors appear unrelated to amplification of the adjacent HER-2/neu oncogene.